Similarities and Differences in Technology Commercialization Between Stanford University and Cleveland Clinic: A Comparative Analysis of Global Leading Academic and Medical Institutions

Currently, scientific research innovation and the translation of achievements in the medical field are progressing with great momentum. Under these circumstances, universities and hospitals, as the primary drivers of innovation in the healthcare sector, have naturally become the focus of the industry.

However, due to differences in the inherent attributes, training systems, and market-oriented platforms of universities and hospitals, there are inevitably significant disparities in their scientific research and innovation models.

Taking Stanford University and the Cleveland Clinic, as “representatives” of research innovation in universities and hospitals, as examples, although their models of innovation and translation in the medical field differ, both have achieved remarkable results and translational performance.

Let’s first look at Stanford University. According to Stanford’s financial reports, from September 2019 to August 2020, the university generated licensing revenue from 847 patented inventions, totaling approximately $114 million.

Let’s look at the Cleveland Clinic. It is reported that in 2019, the Cleveland Clinic disclosed 309 public inventions, filed 4,287 patent applications, and successfully commercialized as many as 92 of them. These efforts attracted over $1.3 billion in investment and generated nearly $90 million in returns for investors.

For Stanford University and the Cleveland Clinic, achieving such a feat was no easy task. So, what did each of them do right? What are the similarities and differences in their models of scientific innovation and translation? Can we, through the lens of Stanford University and the Cleveland Clinic, distill the underlying logic of research innovation at two major medical hubs—universities and hospitals? To answer these questions, VBInsight has conducted an in-depth analysis.

In the process of translating scientific research achievements in the medical field, innovation is the “first mile,” because without innovation, there are no results, let alone translation.

However,How to Cultivate Innovation?? This is a headache for both universities and hospitals.

This pain is mainly reflected in the following aspects: First, due to researchers at universities and hospitals spending long periods in laboratories, they often lack in-depth market research when defining projects, which frequently leads toDisconnection Between Scientific Innovation and Clinical Needs。

Moreover,The “derailment phenomenon” is more severe in universities than in hospitals.. This is because the inherent nature of hospitals allows them to be naturally integrated with clinical work, so hospitals have a better understanding of the urgent problems that need to be solved in clinical practice than universities do.

Secondly, for hospitals, the pain of difficulty in acquiring innovation capabilities is also reflected inLack of Time and Energyaspects. Because physicians are tied up with heavy daily clinical workloads, they have less flexibility compared to university professors.

In light of these realities, how can universities and hospitals tap into their innovative potential? Stanford University and the Cleveland Clinic have offered broadly similar answers.

Overall, both Stanford University and the Cleveland Clinic areCollect and define problems within real-world clinical settings, then screen for high-value questions based on established criteria.

However, specifically, the approaches of Stanford University and the Cleveland Clinic also haveTwo Differences, the first isDifferent Formats for Collecting Questions. Stanford University is primarilyIdentifying Issues During the Observation of Clinical Treatment, and the Cleveland Clinic prefersEncourage researchers to communicate regularly with healthcare professionals., capturing emerging issues from the clinical information they directly provide.

Why does this difference exist?

Because, from the perspective of the Cleveland Clinic, direct communication between professional researchers and clinical healthcare providers is not onlyThe Most Efficient and Cost-Effective Approach, andBoth PartiesThe Clash of Ideas Can Also Yield More Constructive Thoughts, which is highly significant for innovation. However, Stanford University lacks a similarly convenient clinical environment; therefore, it is more effective for researchers to proactively engage with clinical settings to identify problems.

The second difference isDifferent Criteria for Value Assessment. Stanford University is the one that discovered the problemComprehensively evaluate its value by incorporating key information on clinical aspects, stakeholders, and market characteristics., whereas the Cleveland Clinic is the exact opposite; it isContinuously refine the problem to assess its value from multiple dimensions.. These dimensions include: whether the clinical problem genuinely exists, whether its application scenario is sufficiently large, and whether it can be addressed with existing technologies.

So, why is there such a significant difference in the valuation criteria between Stanford University and the Cleveland Clinic? This is still thanks toThe Natural Integration of Hospitals and Clinical Practice, enabling the Cleveland Clinic toGain a clearer view of the details hidden within innovation projects, and to screen them accordingly. For Stanford University, although it lacks clinical advantages, comprehensive and in-depth research into market information can enable researchersA thorough grasp of the issues and a more nuanced understanding of clinical needs。

The “Last Mile” of Translating Scientific and Technological Achievements Is Their Practical Implementation.

However, there are still many problems in the transformation of achievements in universities and hospitals, and the problems in hospitals are more serious. There are mainly the following reasons: First, due to differences in training systems,University Professors Possess Stronger Composite Competencies, thereby better equipped to address and resolve the various challenges encountered in the process of translating achievements into practical applications.

Second, compared with hospitals that focus on clinical care,Universities possess greater market-oriented core competencies, primarily reflected in their more commercialized technology transfer systems and diverse, abundant market resources.。

Given the above circumstances, how do Stanford University and the Cleveland Clinic facilitate technology transfer? The answer is: establishingDedicated technology transfer office, establishing a complete commercialization process encompassing disclosure, evaluation, matchmaking, marketing, and revenue distribution.。

The technology transfer offices of Stanford University and the Cleveland Clinic are, respectively,Office of Technology Licensing(Office of Technology Licensing, hereinafter referred to as OTL) andCleveland Innovation Center(Cleveland Clinic Innovation, hereinafter referred to as CCI), these two technology transfer offices belong to Stanford University and Cleveland Clinic, respectively.

It is generally believed that the most critical aspects of work at technology transfer offices include evaluating technologies, precisely matching technological and market resources, facilitating collaborations, and maximizing returns. How do OTL and CCI approach these areas?

First, inAssessment Technologyaspect, as this is aHighly specializedThe work requires judgment from multiple dimensions, including the purpose of the valuation, the type of value, and market data; therefore, it must be performed by a team of professionals.

At this point, the practices of OTL and CCI are broadly similar. After a project is submitted, both OTL and CCI conveneTechnology Assessment Committeeto determine whether a technology has significant commercial potential. However, the difference lies in the fact that CCI is more comprehensive, as it evaluates both market demand and the feasibility of the invention.

Secondly, atPrecise Alignment of Technology and Market ResourcesIn this regard, due to the different market resources possessed by universities and hospitals, OTL and CCI have their own unique practices.

For Stanford University, thanks to its early practice of leasing one thousand acres of land at extremely low rents for long terms to businesses and industries or to alumni for establishing companies, it has successfully builtIndustrial Park. As technology companies continue to settle in and expand outward, Stanford University alumni and faculty have founded, established, or led thousands of enterprises, seamlessly connecting the university’s research achievements with diverse businesses.

For the Cleveland Clinic, which lacks the market resources to collaborate with numerous enterprises, it therefore hosts annualMedical Innovation Summit, attracting prominent figures from global health systems, the medical academia, and the investment community, thereby securing an “admission ticket” to access market resources.

ThenAdvancing Collaborationaspect. In the process of translating scientific and technological achievements, safeguarding the relevant rights and interests of researchers is a prerequisite for ensuring efficient translation. Among these rights, patent rights are the most critical. However, in practice, this aspect is often overlooked by universities, hospitals, and technology transfer offices alike. Furthermore, due to researchers’ limited familiarity with patent rights, they often lack clarity on what constitutes adequate “protection.”

To address these challenges, OTL and CCI provide specialized legal services to researchers, enabling professional technology licensing officers to assist them in filing patent applications and negotiating patent license agreements.

Finally,How to Maximize Benefits. In this regard, Stanford University and the Cleveland Clinic have clearly defined the revenue-sharing ratios among researchers, their respective laboratories, and their institutions.To safeguard the interests of researchers and incentivize their innovative work。

However, the key difference lies in Stanford University’s highly specific revenue distribution model. It allocates 15% of the proceeds from scientific and technological achievement commercialization to the Office of Technology Licensing (OTL), with the remaining 85% constituting the net income from patent licensing. The former is used for OTL’s commercialization incentives and to cover actual expenses such as patent application and protection costs, while the latter is divided equally into three parts, with one-third each going to the researchers (or research team), their respective school, and their department.